Pharma Update

Crovalimab: Expanding program in complement-mediated diseases Positive Ph III data in PNH filed globally; US filing accepted on 1 Sep Crovalimab (anti-C5 recycling Ab) Broad development program in complement mediated diseases C5 SNP Indication Phl Ph II Ph III COMPOSER Paroxysmal COMMODORE 1 (switch) PNH nocturnal hemoglobinuria COMMODORE 2 (naïve) 5 aHUS Atypical hemolytic uremic syndrome SCD Sickle cell disease COMMODORE 3 (China) COMMUTE-a (adults) COMMUTE-p (pediatric) CROSSWALK-c (chronic) CROSSWALK-a (acute) LN Lupus nephritis Endosome Recycling 4 Receptor, FcRn Lysosome Roche Filed • Uses Chugai's recycling antibody technology (SMART-Ig)1-6 • • Rapid, long-lasting neutralization of C5 in complement mediated diseases Low volume administration supports convenient SC Q4W dosing at home Ph III (COMMODORE 2/1) results in PNH show successful disease control in naïve patients and a favorable benefit-risk profile for patients switching from other C5 inhibitors Clear dosing advantage over current C5 inhibitors with the majority of COMMODORE 2/1 patients preferring crovalimab over previous therapy Filed globally in PNH; first approvals expected in 2024 1 Röth A et al. Blood 2020;135:912-20; 2 Fukuzawa T et al. Sci Rep 2017;7:1080; 3 Sampei Z et al. PLoS One 2018; 13:e0209509; 4 Röth A, Nishimura J. Centro Congressi Federico II 2019; 5 Röth A et al. ASH 2018; 6 Sostelly A et al. ASH 2019; PNH-paroxysmal nocturnal hemoglobinuria; Ab-antibody; SC=subcutaneous; Q4W-every 4 weeks; aHUS-atypical hemolytic uremic syndrome; SCD-Sickle cell disease; LN-lupus nephritis 96 96

View entire presentation